

Reference:	FOI.13068.23
Subject:	Leukaemia treatments
Date of Request:	6 November 2023

Your request and our response

Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.

Patients with acute myeloid leukaemia (AML)

- How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?
 - Azacitidine monotherapy
 - Low dose cytarabine (LoDAC) monotherapy
 - Venetoclax + azacitidine
 - Venetoclax + LoDAC
 - Ivosidenib
 - Intensive chemotherapy-based regimen
 - Other

Answer:

Hywel Dda University Health Board (UHB) provides, within the table overleaf, the number of Acute Myeloid Leukaemia (AML) patients treated with the listed therapies, during the period 1 May to 31 October 2023.

Treatment	Number
Azacitidine monotherapy	*
Low dose cytarabine (LoDAC) monotherapy	0
Venetoclax + azacitidine	*
Venetoclax + LoDAC	0
Ivosidenib	0
Intensive chemotherapy-based regimen	0
Other	0

Where the figures in the tables above and in response to questions 2 and 4 have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients, due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 200 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

2. How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?
- Azacitidine monotherapy
 - Low dose cytarabine (LoDAC) monotherapy
 - Venetoclax + azacitidine
 - Venetoclax + LoDAC
 - Ivosidenib
 - Intensive chemotherapy-based regimen
 - Other

Note: this should only include patients who have started first-line treatment during the 6-month window

Answer:

The UHB provides, within the table overleaf, the number of newly diagnosed AML patients who started first-line treatment with the listed therapies, during the period 1 May to 31 October 2023.

Treatment	Number
Azacitidine monotherapy	*
Low dose cytarabine (LoDAC) monotherapy	0
Venetoclax + azacitidine	0
Venetoclax + LoDAC	0
Ivosidenib	0
Intensive chemotherapy-based regimen	0
Other	0

3. Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many received treatment in line with National Institute for Health and Care Excellence guidance?

Answer:

The UHB is unable to provide you with the exact number of patients, due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. The full explanation of the exemption has been provided in response to question 1.

Patients with chronic lymphocytic leukaemia (CLL)

4. How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include patients who started treatment prior to the 6-month window

Answer:

The UHB provides, within the table below, the number of Chronic Lymphocytic Leukaemia (CLL) patients that received the venetoclax treatments requested, during the period 1 May to 31 October 2023.

Treatment	Number
Venetoclax monotherapy	10
Venetoclax + rituximab	*
Venetoclax + obinutuzumab	9
Venetoclax + ibrutinib	0

5. How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include only patients who have started treatment during the 6-month window

Answer:

The UHB confirms that no CLL patients, new to all lines of treatment, received the venetoclax treatments requested, during the period 1 May to 31 October 2023.